WO2002058635A2 - Immunogenes a la nicotine, anticorps et leurs applications - Google Patents

Immunogenes a la nicotine, anticorps et leurs applications Download PDF

Info

Publication number
WO2002058635A2
WO2002058635A2 PCT/US2002/002146 US0202146W WO02058635A2 WO 2002058635 A2 WO2002058635 A2 WO 2002058635A2 US 0202146 W US0202146 W US 0202146W WO 02058635 A2 WO02058635 A2 WO 02058635A2
Authority
WO
WIPO (PCT)
Prior art keywords
nicotine
compound
immunogen
mmol
antibody
Prior art date
Application number
PCT/US2002/002146
Other languages
English (en)
Other versions
WO2002058635A3 (fr
Inventor
Kim D. Janda
Peter Wirsching
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Priority to AU2002251821A priority Critical patent/AU2002251821A1/en
Publication of WO2002058635A2 publication Critical patent/WO2002058635A2/fr
Publication of WO2002058635A3 publication Critical patent/WO2002058635A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à des immunogènes utiles dans la production d'anticorps anti-nicotine. Lesdits anticorps sont immunoréactifs vis-à-vis des immunogènes et de la nicotine. Font également l'objet de cette invention les immunogènes et les anticorps utilisés dans le traitement du tabagisme.
PCT/US2002/002146 2001-01-26 2002-01-25 Immunogenes a la nicotine, anticorps et leurs applications WO2002058635A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002251821A AU2002251821A1 (en) 2001-01-26 2002-01-25 Nicotine immunogens and antibodies and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26457501P 2001-01-26 2001-01-26
US60/264,575 2001-01-26

Publications (2)

Publication Number Publication Date
WO2002058635A2 true WO2002058635A2 (fr) 2002-08-01
WO2002058635A3 WO2002058635A3 (fr) 2003-03-20

Family

ID=23006669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/002146 WO2002058635A2 (fr) 2001-01-26 2002-01-25 Immunogenes a la nicotine, anticorps et leurs applications

Country Status (2)

Country Link
AU (1) AU2002251821A1 (fr)
WO (1) WO2002058635A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6932971B2 (en) 2002-07-18 2005-08-23 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
WO2009068335A1 (fr) * 2007-11-29 2009-06-04 Cytos Biotechnology Ag Anticorps monoclonaux humains spécifiques à la nicotine
WO2011151807A1 (fr) 2010-06-04 2011-12-08 Pfizer Vaccines Llc Conjugués pour la prévention ou le traitement de la dépendance à la nicotine
US8344111B2 (en) 2007-11-29 2013-01-01 Cytos Biotechnology Ag Human monoclonal nicotine specific antibodies
US20150056251A1 (en) * 2012-02-28 2015-02-26 Cornell University Aav-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
US20150297739A1 (en) * 2012-04-13 2015-10-22 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
WO2015173685A1 (fr) 2014-05-16 2015-11-19 Pfizer Inc. Conjugués utilisables en vue de la prévention ou du traitement de la dépendance à la nicotine et leurs procédés de production
WO2019036419A1 (fr) 2017-08-15 2019-02-21 Kalnik Matthew W Nouveaux anticorps de liaison à la nicotine
WO2019236665A1 (fr) 2018-06-06 2019-12-12 Antidote Therapeutics, Inc. Composition permettant d'améliorer la circulation et de traiter une maladie cardiovasculaire
WO2022111564A1 (fr) * 2020-11-27 2022-06-02 海南凯菲士企业管理合伙企业（有限合伙） Procédé de racémisation et d'utilisation d'un dérivé de pyridine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023076A1 (fr) * 1992-05-20 1993-11-25 The Johns-Hopkins University Therapie utilisant des recepteurs de substitution
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
WO1999061054A1 (fr) * 1998-05-29 1999-12-02 Independent Pharmaceutica Ab Immunogene a la nicotine
WO2000032239A1 (fr) * 1998-12-01 2000-06-08 Nabi Tonjugues haptene-porteur pour traiter et prevenir l"accoutumance a la nicotine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023076A1 (fr) * 1992-05-20 1993-11-25 The Johns-Hopkins University Therapie utilisant des recepteurs de substitution
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
WO1999061054A1 (fr) * 1998-05-29 1999-12-02 Independent Pharmaceutica Ab Immunogene a la nicotine
WO2000032239A1 (fr) * 1998-12-01 2000-06-08 Nabi Tonjugues haptene-porteur pour traiter et prevenir l"accoutumance a la nicotine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CASTRO ET AL.: 'Characterization of antibodies to nicotine' BIOCHEMICAL ARCHIVES vol. 1, 1985, pages 173 - 183, XP002958716 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6932971B2 (en) 2002-07-18 2005-08-23 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
US7452541B2 (en) 2002-07-18 2008-11-18 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
EP2392345A2 (fr) 2002-07-18 2011-12-07 Cytos Biotechnology AG Conjugués vecteurs d'haptène comportant des particules de type viral et utilisations associées
US8187607B2 (en) 2002-07-18 2012-05-29 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
WO2009068335A1 (fr) * 2007-11-29 2009-06-04 Cytos Biotechnology Ag Anticorps monoclonaux humains spécifiques à la nicotine
CN101878228A (zh) * 2007-11-29 2010-11-03 赛托斯生物技术公司 尼古丁特异性人单克隆抗体
EP2319867A1 (fr) * 2007-11-29 2011-05-11 Cytos Biotechnology AG Anticorps spécifiques à la nicotine monoclonale humaine
US8344111B2 (en) 2007-11-29 2013-01-01 Cytos Biotechnology Ag Human monoclonal nicotine specific antibodies
WO2011151807A1 (fr) 2010-06-04 2011-12-08 Pfizer Vaccines Llc Conjugués pour la prévention ou le traitement de la dépendance à la nicotine
US10093947B2 (en) * 2012-02-28 2018-10-09 Cornell University AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
US20150056251A1 (en) * 2012-02-28 2015-02-26 Cornell University Aav-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
US20150297739A1 (en) * 2012-04-13 2015-10-22 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
US10004811B2 (en) * 2012-04-13 2018-06-26 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
WO2015173685A1 (fr) 2014-05-16 2015-11-19 Pfizer Inc. Conjugués utilisables en vue de la prévention ou du traitement de la dépendance à la nicotine et leurs procédés de production
US9303013B2 (en) 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
US9475793B2 (en) 2014-05-16 2016-10-25 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
WO2019036419A1 (fr) 2017-08-15 2019-02-21 Kalnik Matthew W Nouveaux anticorps de liaison à la nicotine
CN111432883A (zh) * 2017-08-15 2020-07-17 安蒂多特疗法公司 新型烟碱结合抗体
US11440970B2 (en) 2017-08-15 2022-09-13 Antidote Therapeutics, Inc. Nicotine-binding antibodies
WO2019236665A1 (fr) 2018-06-06 2019-12-12 Antidote Therapeutics, Inc. Composition permettant d'améliorer la circulation et de traiter une maladie cardiovasculaire
WO2022111564A1 (fr) * 2020-11-27 2022-06-02 海南凯菲士企业管理合伙企业（有限合伙） Procédé de racémisation et d'utilisation d'un dérivé de pyridine

Also Published As

Publication number Publication date
WO2002058635A3 (fr) 2003-03-20
AU2002251821A1 (en) 2002-08-06

Similar Documents

Publication Publication Date Title
Isomura et al. An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis
JP4971542B2 (ja) ニコチン中毒の治療及び予防のためのハプテン−キャリア複合体
JP4270753B2 (ja) ニコチン免疫原
US7446205B2 (en) Method for making nicotine hapten
JPH08511028A (ja) Ｐ物質拮抗剤としてのベンジルオキシキヌクリジン
US11712467B2 (en) Methods of rational nicotine hapten design and uses thereof
AU2017213534B2 (en) Heroin haptens, immunoconjugates and related uses
EA007932B1 (ru) Азабициклопроизводные в качестве антагонистов мускариновых рецепторов
WO2002058635A2 (fr) Immunogenes a la nicotine, anticorps et leurs applications
EP1849780A1 (fr) Vaccin contre la toxicomanie de nicotine
AU1565897A (en) Anti-cocaine vaccine
WO1997021451A9 (fr) Vaccin anti-cocaine
WO2005040338A2 (fr) Immunogenes et anticorps alcaloides contraints et leurs utilisations
CN110452217B (zh) 用于尼古丁疫苗开发的光学纯半抗原
WO2009120954A2 (fr) Immunoconjugués de nicotine
US20050100901A1 (en) Vaccine for treating nicotine addiction
JP2013504618A (ja) ニコチンハプテン、免疫抱合体およびその使用
CN114507178A (zh) 一种芬太尼类蛋白偶联物及其应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP